Skip to main content
OpenTrials
Completed

NCT Number: NCT02225899

BioEnergetics and Metabolomics in Cystic Fibrosis

With better medical care, patients with cystic fibrosis (CF), a life-threatening disease, are enjoying longer lives. As the CF life expectancy increases, conditions such as CF-related diabetes (CFRD) become more prevalent. Nutrition plays a major role in maintaining optimal health in cystic fibrosis (CF). This project is designed to investigate nutrition-related factors, such as diet and body composition, on outcomes in patients with CF. The data generated from this study will be used to inform future nutrition intervention studies in adults with CF and CFRD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Emory University Hospital

Atlanta, Georgia, 30322, United States

About this study

Research methods include blood draws for plasma markers of oxidative stress and metabolomics (the measurement of thousands of small chemicals in the blood), magnetic resonance imaging (MRI, to assess energy capacity and thigh fat), dual energy X-ray absorptiometry (DEXA, to assess total and regional body fat and muscle), and indirect calorimetry (to assess resting energy expenditure and whole body fat oxidation). Clinically-relevant data, such as lung function, CF genotype, and diabetes status will be obtained from the electronic medical record and the CF Registry.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Cystic Fibrosis

Inclusion criteria

  • have confirmed CF diagnosis with at least one Class I to III CFTR mutations
  • age ≥ 18 yrs
  • on a clinically-stable medical regimen for 3 wks
  • no intravenous or oral antibiotics for at least 3 wks prior to study visit

Exclusion criteria

  • current pregnancy
  • unwilling or unable to discontinue enteral tube feeds for one night before the study visit, if applicable
  • most recent FEV1% <40%
  • drug (recreational or prescription) or alcohol abuse
  • pacemaker or any electronic implantable device
  • unable to give informed consent

Healthy volunteers

Inclusion criteria

  • 18-50 yrs of age
  • ambulatory status
  • absence of hospitalization in the previous year except for accidents

Exclusion criteria

  • current pregnancy
  • current active malignant neoplasm or history of malignancy (other than localized basal cell cancer of the skin) during the previous 5 years
  • current respiratory disease including asthma, chronic obstructive pulmonary disorder, or emphysema
  • current chronic autoimmune or pro-inflammatory disease
  • history of tuberculosis, HIV, or other chronic infection
  • previous diagnosis of type 1 or type 2 diabetes with active treatment with insulin or other glucose lowering medication
  • advanced (≥ stage 3) renal disease
  • body mass index (BMI) ≥ 30 kg/m2
  • acute illness (such as a viral infection) within the past 2 weeks
  • current use of any prescription medications that would indicate presence of an acute or chronic medical condition that may influence study results
  • drug (recreational or prescription) or alcohol abuse
  • weight instability (± 10% body weight within the last 6 months) or current participation in weight loss or weight gain program
  • inability to provide informed consent.

Treatment and study plan

Primary outcomes

  1. Acylcarnitine analysis by high-resolution liquid chromatography mass spectrometry

    Time frame: Baseline for cross-sectional study and 1 year for longitudinal study

    This will pe performed using targeted metabolomics methods

Secondary outcomes

  1. quantitative plasma levels of specific plasma acylcarnitines

    Time frame: Baseline for cross-sectional study and 1 year for longitudinal study

    This will be measured in fasted blood

Other outcomes

  1. whole-body fasting fat oxidation

    Time frame: Baseline for cross-sectional study and 1 year for longitudinal study

    This will be assessed using indirect calorimetry

  2. 31P-magnetic resonance spectroscopy (MRS)-derived measures of resting thigh skeletal muscle bioenergetic metabolism

    Time frame: Baseline for cross-sectional study

    This will be assessed using MRI

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

Integration of Nutritional Metabolomics With Bioenergetics in Cystic Fibrosis

Acronym: BEAM-CF

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Aug 26, 2014
Registry last updated
Nov 29, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.